Amicus Therapeutics : Dimerix Licensing Deal Fact Sheet

Published: 2025-05-01 22:40:11 ET FOLD

Published on 05/01/2025 at 22:40

Dimerix and Amicus Therapeutics

Announce Exclusive License Agreement for DMX-200 in the United States

Amicus is thrilled to enter into this collaboration with Dimerix to bring DMX-200 to patients in the U.S., and we are incredibly impressed by their achievements to date.

We look forward to leveraging our regulatory, commercial, medical, and advocacy capabilities to bring this potentially transformative

treatment to people living with FSGS in the U.S. This licensing agreement represents a major step forward in our strategy to strengthen our portfolio and fully aligns with our mission to develop and deliver transformative medicines for people living with rare diseases."

Bradley Campbell

President and Chief Executive Officer, Amicus Therapeutics

DMX-200

Small molecule inhibitor of the

chemokine receptor 2 (CCR2).

Phase 3

DMX-200 is in a pivotal Phase 3 trial. Full enrollment of the study is expected by year end 2025.

FSGS

FSGS, or Focal Segmental Glomerulosclerosis, is a rare and fatal kidney disease with no FDA-approved therapies.

>40,000 people in the U.S

In the U.S., more than 40,000 adults and children are estimated to be living with FSGS. Average time from diagnosis to end-stage kidney disease can be

as short as five years.

Deal Terms

$30 million upfront payment. Next potential milestone payment based on positive data from the Phase 3 FSGS trial.

Up to U.S. $560 million for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales.

Promising Data

In 2024, Dimerix reported positive interim results showing DMX-200 was performing better than placebo in reducing proteinuria.

Disclaimer

Amicus Therapeutics Inc. published this content on May 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 02, 2025 at 02:39 UTC.